Endometriosis Drugs Market Growing at 2.05% CAGR to 2020 Driven by Adoption of OCPs and Intrauterine Devices (IUDs)

Wednesday, July 13, 2016 Drug News
Email Print This Page Comment bookmark
Font : A-A+

RnRMarketResearch.com adds Global Endometriosis Drugs Market 2016-2020 latest research report, the analysts forecast global endometriosis drugs market to grow at a CAGR of 2.05% during the period 2016-2020.

PUNE, India, July 13, 2016 /PRNewswire-iReach/ -- The global endometriosis drugs market analyst says a trend boosting

market growth is the increased focus on IUDs. Current treatment for endometriosis includes the use of GnRH agonists and oral contraceptives along with the use of surgeries. However, all these therapies are associated with many unwanted side effects due to hormonal changes in the body along with the early recurrence of the disease. Hence, the need for an effective replacement for these conventional therapies has led to the development of IUDs. Though IUDs were initially developed for effective birth control, their use has been extended to treat endometriosis. Levonorgestrel intrauterine system (LNG-IUS) devices such as Mirena and Skyla will release progestogen into the body through the IUD at low concentration for an extended period.

(Photo - http://photos.prnewswire.com/prnh/20160713/389096)

Complete report on endometriosis drugs market spread across 70 pages, analyzing 4 major companies and providing 40 data exhibits are now available at http://www.rnrmarketresearch.com/global-endometriosis-drugs-market-2016-2020-market-report.html.

According to the 2016 endometriosis drugs market report, a key growth driver is the increased adoption of OCPs. OCPs also referred to as hormonal pills contain the female hormones, estrogen and progestin similar to that produced by the ovaries. Some of the pills may contain only progestin. Apart from being used as contraceptives, these hormone pills are found to be effective in treating endometriosis. They do not cure endometriosis but are helpful in controlling the pain and preventing the condition from worsening. These medicines are also found to lower the chances of getting endometrial and ovarian cancer, ovarian cysts, certain breast lumps, and also protect the individual from osteoporosis.

The following companies are the key players in the global endometriosis drugs market: AbbVie, AstraZeneca, Bayer HealthCare, and Pfizer. Other prominent vendors in the endometriosis drugs market are: Addex Therapeutics, Astellas Pharma, Debiopharm, ElexoPharm, Endoceutics, Euroscreen, Forendo Pharma, Isifer, Kissei Pharmaceutical, Neurocrine Biosciences, Nippon Shinyaku, ObsEva, Orphagen Pharmaceuticals, Philogen, PregLem, Repros Therapeutics, Roivant Sciences, SK Chemicals, Speciality European Pharma, SYNG Pharmaceuticals, Takeda, United Pharmaceuticals, and ValiPharma.

Order a copy of Global Endometriosis Drugs Market 2016-2020 report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=631346

Global Endometriosis Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Further, endometriosis drugs market report states that one challenge that could hamper market growth is surgery as the primary treatment option.

The report covers the present scenario and the growth prospects of the Global Endometriosis Drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of approved and off-label branded and generic drugs used for the treatment and prevention of endometriosis and related pain. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.

Another related report is Global Women's Health Market 2016-2020, the analysts forecast global women's health market to grow at a CAGR of 3.84% during the period 2016-2020. The limited funding for public health clinics globally has led to a rise in common STIs such as chlamydia, syphilis, and gonorrhea. Such diseases should be treated urgently as they can cause pelvic inflammatory diseases, stillbirths, neonatal infections, and infertility. Various public health institutes highly recommend that women who are sexually active must undergo STI screening once a year. The increase in detections of STIs will positively affect this market. Browse complete report @ http://www.rnrmarketresearch.com/global-womens-health-market-2016-2020-market-report.html

About Us:

RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Media Contact: Ritesh Tiwari, RnRMarketResearch, +1 888 391 5441, sales@rnrmarketresearch.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE RnRMarketResearch

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store